Ann Dermatol.  2013 May;25(2):242-245. 10.5021/ad.2013.25.2.242.

A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria

• Lefevre AC
• Deleuran M
• Vestergaard C

• KMID: 2171798
• DOI: http://doi.org/10.5021/ad.2013.25.2.242

Abstract

No abstract available.

MeSH Terms

Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized
Urticaria
Omalizumab
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized

Figure

• 

  Fig. 1 (A) Average registered with the number of treatments. The shaded area represents the number of patients at the given number of treatment. (B) UAS7 score registered with the number of treatments. The shaded area again illustrates the number of patients. DQLI: dermatological quality of life index, UAS7: urticaria activity score of 7. *p<0.001 as calculated by one-way ANOVA for values at treatment number 1, 2 and 3.

Reference

1. Weller K, Schoepke N, Krause K, Ardelean E, Bräutigam M, Maurer M. Selected urticaria patients benefit from a referral to tertiary care centres--results of an expert survey. J Eur Acad Dermatol Venereol. 2013. 27:e8–e16.

2. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A, et al. Dermatology Section of the European Academy of Allergology and Clinical Immunology. Global Allergy and Asthma European Network. European Dermatology Forum. World Allergy Organization. Dermatology Section of the European Academy of Allergology and Clinical Immunology. Global Allergy and Asthma European Network. European Dermatology Forum. World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009. 64:1417–1426.

3. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. Dermatology Section of the European Academy of Allergology and Clinical Immunology. Global Allergy and Asthma European Network. European Dermatology Forum. World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009. 64:1427–1443.

4. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997. 158:1438–1445.

5. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004. 114:527–530.

6. Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008. 63:777–780.

7. Finlay AY, Khan GK. Dermatology Life Quality Index (DQLI)- -a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994. 19:210–216.

8. Ivyanskiy I, Sand C, Thomsen SF. Omalizumab for chronic urticaria: a case series and overview of the literature. Case Rep Dermatol. 2012. 4:19–26.

9. Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods. 2005. 303:81–91.

10. Steiss JO, Schmidt A, Nährlich L, Zimmer KP, Rudloff S. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Allergy Asthma Proc. 2012. 33:77–81.